Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC

January 25th 2020

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer

January 25th 2020

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC

January 25th 2020

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC

January 25th 2020

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.

Nivolumab/Ramucirumab Plus Chemo Highly Active in Second-Line Gastric Cancer

January 25th 2020

The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.

Dr. Macarulla Discusses Rapid Progressors in the POLO Trial

January 24th 2020

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

Larotrectinib Efficacy Confirmed in TRK+ GI Cancer

January 24th 2020

The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.

Pembrolizumab Shows Enhanced Efficacy in High PD-L1 Gastric Cancer

January 24th 2020

Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Study Supports TKI Response as Predictor of Survival in HCC

January 21st 2019

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

Dr. Strosberg Discusses Results for KEYNOTE-158

January 21st 2019

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

January 20th 2019

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

Single-Agent Durvalumab Elicits Responses in MSI-H CRC

January 20th 2019

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC

January 20th 2019

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer

January 20th 2019

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

January 19th 2019

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer

January 19th 2019

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer

January 19th 2019

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

Dr. Molena on Challenges With Endoscopic Resection in Esophageal Cancers

January 19th 2019

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.